News

Stay Updated! In The World Of Investments!
Sensex 48253.51 0 (0.00%)

Shilpa Medicare Latest News

27

Apr, 2021

Shilpa Medicare’s US operating company sues Novartis Pharmaceutical Corporation

Shilpa Medicare’s US operating company -- Shilpa Pharma, Inc. has filed patent infringement lawsuit against Novartis Pharmaceutical Corporation in the United States District court for the district of Delaware ...

Read More

05

Mar, 2021

Shilpa Medicare gets tentative USFDA’s nod for Apremilast tablets

Shilpa Medicare has received tentative approval from the US health regulator for Apremilast tablets, used in the treatment of psoriatic arthritis. The newly approved product is a generic equivalent of reference listed drug (RLD...

Read More

04

Mar, 2021

Shilpa Medicare surges on launching first women intimate cleansing spray ‘SwatchShil’

Shilpa Medicare is currently trading at Rs. 386.50, up by 17.50 points or 4.74% from its previous closing of Rs. 369.00 on the BSE.

The scrip opened at Rs. 372.90 and has touched a ...

Read More

04

Mar, 2021

Shilpa Medicare launches first women intimate cleansing spray ‘SwatchShil’

Shilpa Medicare has launched India's First Women intimate cleansing spray under the brand name ‘SwatchShil’ and shall be available in Jasmine and Floral Fragrance in 100ml Spray pack. ‘SwatchS...

Read More

18

Feb, 2021

Shilpa Medicare tumbles on receiving import alert

Shilpa Medicare is currently trading at Rs. 385.85, down by 40.25 points or 9.45% from its previous closing of Rs. 426.10 on the BSE.

The scrip opened at Rs. 425.00 and has touched ...

Read More

18

Feb, 2021

Shilpa Medicare receives import alert

Shilpa Medicare has received an Import Alert 66-40 on February 17, 2021, pursuant to the USFDA inspection of the Unit 4, Jadcherla, Telangana facility from February 13 - 20 and February 24-25, 2020.

Read More

15

Feb, 2021

Shilpa Medicare launches Sunitinib Capsules

Shilpa Medicare has launched Sunitinib Capsules, under the brand name ‘SUNISHIL’. Three strengths of Sunitinib capsules 12. 5 mg, 25 mg and 50 mg is launched at an attractive price for the benefit of patients. Sunit...

Read More

13

Feb, 2021

Shilpa Medicare reports Profit after tax of Rs 168.79 Mln, in the December 2020 quarter

The sales is pegged at Rs. 1713.00 millions for the December 2020 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 2169.29 millions during the year-ago period.A big decline of -70.53% was reported for the quarter ended D...

Read More

16

Dec, 2020

Ind-Ra assigns Shilpa Medicare’s long term rating at ‘A+’

Credit rating agency-- India Ratings and Research (Ind-Ra) has assigned rating to Shilpa Medicare’s long term rating at ‘A+/Stable’ and short term rating at ‘A+/Stable/A1’ against the existing rati...

Read More

11

Nov, 2020

Shilpa Medicare informs about disclosure

Shilpa Medicare has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vishnukant C Bhutada.

Read More

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback